

The information in the press release is intended for investors.

Isofol invites to investor meeting on March 19

GOTHENBURG, Sweden, March 1, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors and shareholders to an investor meeting to present the company’s strategy and clinical development programme for the drug candidate arfolitixorin.

Isofol invites to an investor meeting where the board and management will present the strategy going forward and the clinical development programme for arfolitixorin. The meeting will be held in Gothenburg but can also be followed online. The presentation is mainly held in Swedish and participants will have the opportunity to ask questions, both on site and online.

Date and time

Tuesday March 19, at 18.00-19.00 (webcast)

Venue

Arvid Wallgrens Backe 20, 5th floor, Gothenburg

Agenda

17.30–18.00 Registration

18.00–19.00 Presentation of the strategy 2024-2026
Presentation of the clinical program
Q&A

19.00-19.55 Mingle and refreshments

Registration

You are welcome to register via the company’s website, no later than March 10:

<https://isofolmedical.com/investormeeting/>

Please note that the number of seats is limited in the venue. When the registration period has expired you will receive a confirmation by e-mail with a web link included if you want to follow the investor meeting online. This link will be published on Isofol’s website after March 10.

The presentation will also be available on Isofol’s website afterward.

For more information, please contact

Isofol Medical AB (publ)

Petter Segelman Lindqvist, CEO

E-mail: petter.s.lindqvist@isofolmedical.com

Telephone: +46 (0)739 60 12 56

The information was submitted for publication, through the agency of the contact person set out above, at 10:30 CET, on March 1, 2024.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofofmedical.com